OAZ2 and neoplasm: Consequently, by revealing how OAZ2 is regulated by miR-34a at the posttranscriptional level, our findings suggest that miR-34a mimic and OAZ2 agonist may be repositioned to suppress cancer progression, dampen tumor evolution, and decrease the probability of adverse outcomes by MDR in colon cancer.